Portal de Periódicos da CAPES

Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey

2020; BMJ; Volume: 79; Issue: 9 Linguagem: Inglês

10.1136/annrheumdis-2020-217600

1468-2060

Alessandro Tomelleri, Silvia Sartorelli, Corrado Campochiaro, Elena Baldissera, Lorenzo Dagna,

Dermatological and COVID-19 studies

Severe infections represent one of the major complications of immunosuppressive therapy.1 Great concern among rheumatologists has consequently raised by the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19).2 3 Italy has represented the European epicentre of this global pandemic, with more than 140 000 confirmed cases as of 11 April 2020.4 We evaluated the impact of SARS-CoV-2 infection among patients with large-vessel vasculitis (LVV) followed up at our LVV-Clinic in Milan, Lombardy, the Italian region with the highest rate of SARS-CoV-2 infections.5 A phone survey was conducted among these patients between 2 and 10 April 2020, 6 weeks after the COVID-19 outbreak in Italy. The survey consisted of the following questions: (1) Have you been diagnosed with COVID-19? (2) Since the beginning of COVID-19 outbreak, have you experienced one of the following symptoms: sore throat, non-productive cough, fever >37.5°C, reduced smelling or tasting, flu-like symptoms? (3) Have you been in contact with a COVID-19 patient? (4) Have you regularly been taking your LVV medications? …